These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 6408435)
1. [Biosynthetic human insulin. Comparison of the activity profile of human NPH-insulin and swine NPH-insulin in type I diabetics]. Etti H; Haupt E MMW Munch Med Wochenschr; 1983 May; Suppl 1():S53-6. PubMed ID: 6408435 [No Abstract] [Full Text] [Related]
2. [Comparison of the effects of protamine-bound NPH porcine insulin and NPH human insulin in type 1 and 2 diabetes]. Renner R; Vocke K; Hepp KD Dtsch Med Wochenschr; 1986 Aug; 111(35):1316-20. PubMed ID: 3743441 [TBL] [Abstract][Full Text] [Related]
3. [Blood sugar profile of various mixtures of regular BHI and basal BHI (NPH) in type I and type II diabetic patients]. Renner R; Vocke K; Hepp KD MMW Munch Med Wochenschr; 1983 May; Suppl 1():S57-62. PubMed ID: 6408436 [No Abstract] [Full Text] [Related]
4. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145 [TBL] [Abstract][Full Text] [Related]
5. Insulin analogues and their potential in the management of diabetes mellitus. Bolli GB; Di Marchi RD; Park GD; Pramming S; Koivisto VA Diabetologia; 1999 Oct; 42(10):1151-67. PubMed ID: 10525654 [No Abstract] [Full Text] [Related]
6. [Use of fixed-combination preparations of regular BHI and basal BHI (NPH) in type I diabetics]. Landgraf R; Landgraf-Leurs MM MMW Munch Med Wochenschr; 1983 May; Suppl 1():S63-8. PubMed ID: 6408437 [No Abstract] [Full Text] [Related]
7. [12 month's therapy with biosynthetic human insulin. Results of a double-blind comparative study with swine and bovine insulin in insulin-dependent diabetics during a multicenter study]. Beyer J; Haas R; Enzmann F; Lauerbach M; Rademacher J; Althoff PH; Bachmann W; Brandstetter K; Cordes U; Dannehl A; Düntsch G; Heun K; Kerp L; Lotz N; Mehnert H; Mitzkat HJ; Petersen K; Rosak C; Sailer D; Schlüter K; Schöffling K; Schröder KE; Schumm P MMW Munch Med Wochenschr; 1983 May; Suppl 1():S69-79. PubMed ID: 6408438 [No Abstract] [Full Text] [Related]
8. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal. Rosak C; Jung R; Hofmann U Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882 [TBL] [Abstract][Full Text] [Related]
10. [Immediate protamine sulphate allergy in an insulin-treated diabetic patient]. Petäys T; Kiistala R; Mäkinen-Kiljunen S Duodecim; 1999; 115(5):517-20. PubMed ID: 11830901 [No Abstract] [Full Text] [Related]
11. Comparison of the absorption and biological activity of NPH human insulin (recombinant DNA) and NPH porcine insulin injected subcutaneously in type II diabetic patients. Bannai C; Kawai K; Murayama Y; Yamashita K Horm Metab Res; 1986 Nov; 18(11):784-5. PubMed ID: 3539738 [No Abstract] [Full Text] [Related]
13. Combinations of oral hypoglycemic drugs in obese, insulin-resistant diabetics. Fineberg SK Geriatrics; 1968 Sep; 23(9):137-46. PubMed ID: 5673663 [No Abstract] [Full Text] [Related]
14. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Luzio SD; Beck P; Owens DR Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275 [TBL] [Abstract][Full Text] [Related]
16. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Päivärinta M; Tapanainen P; Veijola R Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431 [TBL] [Abstract][Full Text] [Related]
17. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Peterson GE Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343 [TBL] [Abstract][Full Text] [Related]
18. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076 [TBL] [Abstract][Full Text] [Related]
19. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)]. Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of insulin of various origins. Reeves WG Neth J Med; 1985; 28 Suppl 1():43-6. PubMed ID: 3892338 [No Abstract] [Full Text] [Related] [Next] [New Search]